<DOC>
	<DOCNO>NCT01863667</DOCNO>
	<brief_summary>This trial ass safety efficacy omarigliptin ( MK-3102 ) compare sulfonylurea , glimepiride , type 2 diabetes mellitus participant metformin intolerant contraindication use metformin . The primary hypothesis 54 week , mean change baseline hemoglobin A1c ( A1C ) participant treat omarigliptin non-inferior compare participant treat glimepiride .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Omarigliptin ( MK-3102 ) Compared With Glimepiride Participants With Type 2 Diabetes Mellitus Whom Metformin Inappropriate ( MK-3102-027 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed type 2 diabetes mellitus Have intolerability metformin ≥1000 mg/day contraindication use metformin Females reproductive potential agree remain abstinent use partner use 2 acceptable method birth control History type 1 diabetes mellitus history ketoacidosis assess investigator possibly type 1 diabetes Has treat : 1 . A thiazolidinedione ( TZD ) within 4 month study participation , 2 . A glucagonlike peptide1 ( GLP1 ) receptor mimetic agonist ( exenatide liraglutide ) within 6 month study participation , 3 . Insulin within 12 week prior study participation , 4 . Dual antihyperglycemic agent ( AHA ) therapy within 12 week study participation ( 4 month component dual AHA therapy TZD ) 5 . Omarigliptin ( MK3102 ) time prior study participation On weight loss program maintenance phase ; start weight loss medication past 6 month ; undergone bariatric surgery within 12 month prior study participation Medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Human immunodeficiency virus ( HIV ) New worsen coronary heart disease , congestive heart failure , myocardial infarction , unstable angina , coronary artery intervention , stroke transient ischemic neurological disorder within past 3 month History malignancy ≤5 year prior study participation except adequately treat basal cell squamous cell skin cancer , situ cervical cancer Clinically important hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) Pregnant breastfeeding , expect conceive donate egg trial , include 21 day follow last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>